Presentation of the annual report 2009

Published: 15 February 2010Financial Investment & Stock

Photocure ASA will present its 4th quarter and annual report 2009 on Friday 19th of February 2010 at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway. The presentation will begin at 11.30 (CET) and representatives from the company will be Kjetil Hestdal, President & CEO and Christian Fekete, CFO.

The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation through a live webcast.
 
Lunch is served from 11:00 (CET).
 
The presentation is scheduled to conclude at 12:15 (CET).
Please register your attendance at Photocure ASA by Thursday 18th February at 14:00 (CET).
Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).

Best regards,

Christian Fekete, CFO
Photocure ASA
Hoffsveien 48
0377 Oslo, Norway
Telephone: +47 22 06 22 10
Telefax:  +47 22 06 22 18
www.photocure.com

 
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
 
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.
 
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM)platform.
 
For more information about Photocure, visit our website at www.photocure.com.

 

Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.
 
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events